Brief: Probi And China National Pharmaceutical Foreign Trade Corporation Sign License & Supply Agreement
22/04/2021 13:01
April 22 (Reuters) - Probi AB PROB.ST :
* PROBI AND CHINA NATIONAL PHARMACEUTICAL FOREIGN TRADE
CORPORATION HAVE SIGNED A LICENSE & SUPPLY AGREEMENT
* PARTNERSHIP TO EXPAND OFFERING OF PREMIUM PROBIOTIC
OFFERINGS IN
CHINESE MARKET
Source text for Eikon: ID:nWkrcdCrfX
Further company coverage: PROB.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587696600;))
Recent news on Probi AB
See all newsBrief: Probi To Delist, Last Trading Day Is Feb 12, 2025
Brief: Probi Applies For Delisting And Convenes An Extraordinary General Meeting
Brief: Probi Says Independent Bid Committee Of Co Recommends Shareholders To Accept Cash-Based Public Takeover Offer Submitted By Symrise AG
Probi shares surge in line with premium after Symrise buyout offer
Brief: Symrise Announces Public Offer To Shareholders Of Probi To Tender All Shares